35 percent of patients with breast cancer worried about genetic risks to themselves, family members
the ONA take:
According to a new study conducted at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, researchers have found that a third of women diagnosed with breast cancer are concerned about the genetic risk of a family member developing cancer or developing other cancers themselves.
For the study, researchers surveyed 1,536 women who had been treated for breast cancer that were included in the Surveillance, Epidemiology and End Results (SEER) databases.
Results showed that 35% of women with breast cancer expressed a strong desire for genetic testing, while 43% did not have a discussion about genetic testing with a health care professional.
The study also found that racial minority participants were less likely than white patients to discuss genetic testing with a health care professional despite a strong desire to do so.
Researchers found that many patients, particularly Latinas who spoke only Spanish, were concerned that their loved ones might get breast cancer in the future due to inherited risk.
Study results were published in the Journal of Clinical Oncology.
A third of women diagnosed with breast cancer are concerned about the genetic risk of a family member developing cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|